(P-1072) Evaluation of the Spontaneous Mutation Frequencies of SPR719 Alone and in Combination with Other Agents Used to Treat Mycobacterium avium Complex Pulmonary Disease

Friday, October 18, 2024

12:15 PM – 1:30 PM US PT

Location: Halls JK

Presenting Author(s)

OW

Olivia Walser, MS

Microbiologics
Kalamazoo, Michigan, United States
ND

Naomi DeLaet, BS

Microbiologics
kalamazoo, Michigan, United States
ZL

Zach Leer, MLS (ASCP)CM

Microbiologics
kalamazoo, Michigan, United States
MT

Mary Thwaites, MS

microbiologics
kalamazoo, Michigan, United States
DH

David A. Hufnagel, PhD

Microbiologics
Kalamazoo, Michigan, United States
NC

Nicole Cotroneo, B.S.

Director
Spero Therapeutics
Cambridge, Massachusetts, United States
Ian A. Critchley, PhD

Vice President, Head
Spero Therapeutics
Cambridge, Massachusetts, United States
Kamal Hamed, MD, MPH

Chief Medical Officer
Spero Therapeutics, Inc.
Cambridge, Massachusetts, United States